Как победить диабет. Руководство по питанию и образу жизни

11. Vreman RA, Goodell AJ, Rodriguez LA, Porco TC, Lustig RH, Kahn JG. Health and economic benefits of reducing sugar intake in the USA, including effects via non-alcoholic fatty liver disease: A microsimulation model. BMJ Open. 2017; 7(8): e013543.

12. Stanhope KL. Sugar consumption, metabolic disease and obesity: The state of the controversy HHS Public Access. Crit Rev Clin Lab Sci. 2016; 53(1): 52–67.

13. World Cancer Research Fund, American Institute for Cancer Research. Food, Nutrition, Physical Activity and the PreventionofCancer: AGlobalPerspective. Washington, D.C., 2007.

14. Key TJ, Spencer EA. Carbohydrates and cancer: an overview of the epidemiological evidence. Eur J Clin Nutr. 2007; 61(S1): S112–S121.

15. Kabat GC, Kim MY, Strickler HD, et al. A longitudinal study of serum insulin and glucose levels in relation to colorectal cancer risk among postmenopausal women. Br J Cancer. 2012; 106(1): 227–232.

16. Romanos-Nanclares A, Toledo E, Gardeazabal I, Jiménez-Moleón JJ, Martínez-González MA, Gea A. Sugar-sweetened beverage consumption and incidence of breast cancer: The Seguimiento Universidad de Navarra (SUN) Project. Eur J Nutr. October 2018.

17. Institute of Medicine. Dietary Reference Intakes for Energy, Carbohydrate, Fiber,Fat,FattyAcids,Cholesterol,Protein,andAminoAcids. Washington, D.C.: National Academies Press. 2002.

18. van Dam RM, Seidell JC. Carbohydrate intake and obesity. Eur J Clin Nutr. 2007; 61(S1): S75–S99.

19. Ruanpeng D, Thongprayoon C, Cheungpasitporn W, Harindhanavudhi T. Sugar and artificially sweetened beverages linked to obesity: A systematic review and meta-analysis. QJM An Int J Med. 2017; 110(8): 513–520.

20. Paschos P, Paletas K. Non-alcoholic fatty liver disease and metabolic syndrome. Hippokratia. 2009; 13(1): 9–19.

21. Vreman RA, Goodell AJ, Rodriguez LA, et al. Health and economic benefits of reducing sugar intake in the USA, including effects via non-alcoholic fatty liver disease: A microsimulation model. BMJ Open. 2017; 7(8): e013543.

22. Nier A, Brandt A, Conzelmann I, et al. Non-alcoholic fatty liver disease in overweight children: Role of fructose intake and dietary pattern. Nutrients. 2018; 10(9): 1329.

23. Nseir W, Nassar F, Assy N. Soft drinks consumption and nonalcoholic fatty liver disease. World J Gastroenterol. 2010; 16(21): 2579–2588.

24. Ter Horst KW, Serlie MJ. Fructose consumption, lipogenesis, and non-alcoholic fatty liver disease. Nutrients. 2017; 9(9).

25. Jamnik J, Rehman S, Blanco Mejia S, et al. Fructose intake and risk of gout and hyperuricemia: A systematic review and meta-analysis of prospective cohort studies. BMJ Open. 2016; 6(10): e013191.

26. Ebrahimpour-koujan S, Saneei P, Larijani B, Esmaillzadeh A. Consumption of sugar sweetened beverages and dietary fructose in relation to risk of gout and hyperuricemia: A systematic review and meta-analysis. Crit Rev Food Sci Nutr. October 2018: 1–10.

27. O’Connor L, Imamura F, Brage S, Griffin SJ, Wareham NJ, Forouhi NG. Intakes and sources of dietary sugars and their association with metabolic and inflammatory markers. Clin Nutr. 2018; 37(4): 1313–1322.

28. Stegenga ME, Crabben SN van der, Dessing MC, et al. Effect of acute hyperglycaemia and / or hyperinsulinaemia on proinflammatory gene expression, cytokine production and neutrophil function in humans. Diabet Med. 2008; 25(2): 157–164.

29. Della Corte K, Perrar I, Penczynski K, et al. Effect of dietary sugar intake on biomarkers of subclinical inflammation: A systematic review and meta-analysis of intervention studies. Nutrients. 2018; 10(5): 606.

30. Takeuchi M, Iwaki M, Takino J, et al. Immunological detection of fructose-derived advanced glycation end-products. Lab Invest. 2010; 90(7): 1117–1127.

31. Gugliucci A. Formation of fructose-mediated advanced glycation end products and their roles in metabolic and inflammatory diseases. Adv Nutr An Int Rev J. 2017; 8(1): 54–62.

32. Jang C, Hui S, Lu W, et al. The small intestine converts dietary fructose into glucose and organic acids. Cell Metab. 2018; 27(2): 351–361.e3.

33. Schwarz J-M, Noworolski SM, Erkin-Cakmak A, et al. Effects of dietary fructose restriction on liver fat, de novo lipogenesis, and insulin kinetics in children with obesity. Gastroenterology. 2017; 153(3): 743–752.

34. Schwarz J-M, Noworolski SM, Wen MJ, et al. Effect of a high-fructose weight-maintaining diet on lipogenesis and liver fat. J Clin Endocrinol Metab. 2015; 100(6): 2434–2442.